Emerging pharmacotherapy for cancer patients with cognitive dysfunction.

Published

Journal Article (Review)

Advances in the diagnosis and multi-modality treatment of cancer have increased survival rates for many cancer types leading to an increasing load of long-term sequelae of therapy, including that of cognitive dysfunction. The cytotoxic nature of chemotherapeutic agents may also reduce neurogenesis, a key component of the physiology of memory and cognition, with ramifications for the patient's mood and other cognition disorders. Similarly radiotherapy employed as a therapeutic or prophylactic tool in the treatment of primary or metastatic disease may significantly affect cognition. A number of emerging pharmacotherapies are under investigation for the treatment of cognitive dysfunction experienced by cancer patients. Recent data from clinical trials is reviewed involving the stimulants modafinil and methylphenidate, mood stabiliser lithium, anti-Alzheimer's drugs memantine and donepezil, as well as other agents which are currently being explored within dementia, animal, and cell culture models to evaluate their use in treating cognitive dysfunction.

Full Text

Duke Authors

Cited Authors

  • Davis, J; Ahlberg, FM; Berk, M; Ashley, DM; Khasraw, M

Published Date

  • January 2013

Published In

Volume / Issue

  • 13 /

Start / End Page

  • 153 -

PubMed ID

  • 24156319

Pubmed Central ID

  • 24156319

Electronic International Standard Serial Number (EISSN)

  • 1471-2377

International Standard Serial Number (ISSN)

  • 1471-2377

Digital Object Identifier (DOI)

  • 10.1186/1471-2377-13-153

Language

  • eng